Our Mission
The PCCTC’s distinguished investigators work together on a single mission: to design, implement, and complete hypothesis-driven prostate cancer studies, translating scientific discoveries to improved standards of care. We offer contract research organization (CRO) services and leverage academic consortium engagement to carry out this mission, ensuring efficient study selection, reporting, site management, clinical operations, and data analyses.
Our History
The PCCTC was initiated in 2005 by the Prostate Cancer Foundation (PCF) and the U.S. Department of Defense (DOD) Prostate Cancer Research Program (PCRP) in response to critically unmet needs in prostate cancer clinical research identified by physician investigators and patient advocates. To fulfill our mission, we developed a unique infrastructure which has fostered a culture of transparent project co-development between investigators, research sites, and industry partners. Established as an independent entity in 2014, the PCCTC, LLC is now the nation’s premier multicenter contract research organization (CRO) and academic clinical consortium specializing in cutting-edge prostate cancer research. Through the collaborative nature and intellectual synergy of our leadership, the PCCTC remains poised to make a significant impact on the lives of patients by keeping the pipeline primed with the most promising novel therapies and validated biomarkers
PCCTC investigator-led studies represent >22% of active early-phase prostate cancer clinical trials in the US.
The PCCTC has contributed to the advancement of 27 therapeutic candidates to phase 3 study, nine of which are fully approved by the FDA.
PCCTC research has resulted in the publication of over 500 abstracts and 190 academic papers.
Over 16,200 participants have been enrolled onto 305 PCCTC studies.
Our Leadership
Management Team
Jake Vinson
CEO
Rebecca Green
Director of Clinical Operations
Howard I. Scher, MD
Scientific Oversight Committee Chair Emeritus
Michelle Karlin
Director of Business Development and Operations
Michael J. Morris, MD
Scientific Oversight Committee Chair
Joy Allen, PhD
Director of Clinical Data Management
Sarah Wise
Senior Director of Research Operations
Charles J. Ryan, MD
Medical Director
Travis Gerke, ScD
Director of Clinical Data Science
Scientific Oversight Committee
Michael J. Morris, MD (Chair), Memorial Sloan Kettering Cancer Center
Mary-Ellen Taplin, MD, Dana-Farber / Harvard Cancer Center
Andrew Armstrong, MD, MSc, Duke Comprehensive Cancer Center
Channing Paller, MD, Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center
Alexandra Sokolova, MD, Oregon Health and Science University
Knight Cancer Institute
Rahul Aggarwal, MD, University of California, San Francisco
Russell Szmulewitz, MD, University of Chicago
Emmanuel Antonarakis, MD, University of Minnesota Twin Cities
Heather Cheng, MD, PhD, University of Washington Fred Hutchinson
Cancer Research Center
Glenn Liu, MD, University of Wisconsin Carbone Cancer Center
Frank Cackowski, MD, PhD, Barbara Ann Karmanos Cancer Institute
Scott Tagawa, MD, MS, Weill Cornell Medical College & Columbia University
Our Participating Clinical Research Sites
Over 200 clinical research sites—academic medical centers, community hospitals, and research institutions—collaborate on PCCTC studies.
Current list available upon request.
